Can a Grid-Shaped radiation boost ease symptoms of bulky tumors?

NCT ID NCT07856394

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 02, 2026 · Last updated Oct 08, 2026 · Updated 2 times

Summary

Researchers are testing whether adding a specialized radiation technique called spatially fractionated radiation therapy (SFRT) to standard palliative radiation helps people with large, inoperable solid tumors feel better. SFRT delivers high doses of radiation in a grid pattern, leaving gaps that may spare healthy tissue. The trial enrolls about 100 adults with bulky tumors larger than 5 cm that cannot be removed by surgery. Participants receive either standard palliative radiation alone or standard radiation plus the SFRT boost. The main goal is to see if one month after treatment, patients report that their most bothersome symptom, such as pain or trouble breathing, is moderately or very much better.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
spatially fractionated radiation therapy added to standard palliative external beam radiation therapy
What this could lead to
If it works, this could give doctors a way to ease pain, bleeding, or breathing problems from large tumors that cannot be removed.
What could go wrong
This is a phase II trial, so it tests whether the approach helps symptoms, not whether it cures cancer. Adding a radiation boost may not improve symptoms more than standard palliative radiation alone, and it could cause extra side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2026

Expected to finish

Sep 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

15 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically proven primary or metastatic solid malignant tumors from any histologic subtype * Measurable primary or metastatic bulky tumor defined as tumor \> 5 cm in largest dimension not eligible for surgical resection or not an ideal candidate for alternative local therapies, e.g., cryoablation, etc. * Eastern Cooperative Oncology Group (ECOG) performance status 0-3 assessed within 30 days of enrollment * Estimated life expectancy \> 3 months, as judged by treating clinician * Patients must sign Institutional Review Board (IRB) approved study specific informed consent * Patients must complete all required pre-entry tests within the specified time limits * Patients must be able to start treatment (radiation) within 60 days of study registration * Patients must be at least 15 years old * A minimum most prominent symptom intensity score reported by the patient of \>= 5 on an 11-point symptom intensity scale (item 4.3.2), clearly related to the target lesion, within one the following: pain, dyspnea, hemorrhage, or dysphagia Exclusion Criteria: * Prior RT to the current target site \< 3 months from randomization * Intracranial invasion by the proposed tumor target or tumor target intertwined with bowel loops * Concurrent systemic therapy (e.g., chemotherapy, immunotherapy) during RT delivery will not be an exclusion condition * Active rectal diverticulitis, Crohn's disease affecting the rectum, or ulcerative colitis (non-active diverticulitis and Crohn's disease not affecting the rectum are allowed), for patients whose target tumor is in the pelvis * Major medical, addictive, or psychiatric illness which in the investigator's opinion, will prevent the consent process, completion of the treatment and/or interfere with follow-up. Consent by legal authorized representative is not permitted for this study * History of myocardial infarction or decompensated congestive heart failure (CHF) within the last 6 months * On a transplant list * Any of the following are excluded because this study involves ionizing radiation: * Pregnant persons * Nursing persons * Persons of childbearing potential who are unwilling to employ adequate birth control measures will be asked to stay on adequate forms of birth control until study intervention (therapy) is finished

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Malignant tumor are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    2 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Mayo Clinic in Arizona

    RECRUITING

    Scottsdale, Arizona, 85259, United States

    Contact Email: •••••@•••••

  • Mayo Clinic in Rochester

    NOT_YET_RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.